PHA-793887, a novel potent inhibitor of Cdk, target on kinds of cyclin-dependent kinase under low concentrations and poses high activity against several cancer cell lines. The application of PHA793887 revealed that PHA793887 has strong antineoplastic activity at low does. Additionally, this inhibitor has potential activity in mice model. Regardless of any specific chromosomal aberration, in vitro, PHA-793887 was cytotoxic for leukemic cell lines, with IC50 ranging from 0.3 to 7M (mean: 2.9M). Contrastively, the drug was not cytotoxic for CD34+ hematopoietic stem cells or unstimulated peripheral blood mononuclear cells at these doses. PHA-793887 showed very high activity against leukemia cell lines in colony assays, with an IC50
Please Rate this Article 5 out of 54 out of 53 out of 52 out of 51 out of 5
Not yet Rated